Flow injection analysis vs. ultra high performance liquid chromatography coupled with tandem mass spectrometry for determination of imatinib in human plasma

Clinica Chimica Acta

Volumn 411, Issue 23-24, 2010, Pages 1957-1962

  Mičová, Kateřina ^a   Friedeckỳ, David ^a   Faber, Edgar ^a   Polỳnková, Adriana ^a   Adam, Tomáš ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Flow injection analysis; Human plasma; Imatinib; Liquid chromatography; Mass spectrometry; Therapeutic drug monitoring

Indexed keywords

IMATINIB;

ARTICLE; BLOOD SAMPLING; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG DETERMINATION; DRUG MONITORING; DRUG STRUCTURE; FLOW INJECTION ANALYSIS; FLOW RATE; HIGH THROUGHPUT SCREENING; HUMAN; INTERMETHOD COMPARISON; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REACTION ANALYSIS; TANDEM MASS SPECTROMETRY; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS;

EID: 77957753398     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.08.014     Document Type: Article

References (23)

1. Nowell P.C., Hungerford D.A. A minute chromosome in human chronic granulocytic leukaemia. Science 1960, 132:1497-1501.
2. Lugo T.G., Pendergast A.M., Muller A.J., Witte O.N. Tyrosne kinase activity and transformation potency of bcr-abl oncogene products. Science 1990, 340:1330-1340.
3. Druker B.J., Tamura S., Buchdunger E., et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 1996, 2:561-566.
4. Baccarani M., Saglio G., Goldman J.M., et al. Evolving concepts in the management of chronic myeloid leukemia. Recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006, 108:1809-1820.
5. Gorre M.E., Mohammed M., Ellwood K., et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001, 293:876-880.
6. Picard S., Titier K., Etienne G., et al. Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia. Blood 2007, 109:3469-3499.
7. Cortes J.E., Egorin M.J., Guilhot F., Molimard M., Mahon F.X. Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy in chronic myeloid leukemia. Leukemia 2009, 23:1537-1544.
8. Rodríguez-Flores J., Berzas J.J., Castaneda G., Rodríguez N. Direct and fast capillary zone electrophoresic method for the determination of Gleevec and its main metabolite in human urine. J Chromatogr B 2003, 794:381-388.
9. Rodríguez-Flores J., Berzas Nevado J.J., Contento Salcedo A.M., Cabello Díaz M.P. Nonaqueous capillary electrophoresis metod for the analysis of gleevec and its main metabolite in human urine. J Chromatogr A 2005, 1068:175-182.
10. De Francia S., D'Avolio A., De Martino F., et al. New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma. J Chromatogr B 2009, 877:1721-1726.
11. Titier K., Picard S., Ducint D., et al. Quantification of imatinib in human plasma by high-performance liquid chromatography-tandem mass spectrometry. Ther Drug Monit 2005, 27:634-640.
12. Parise R.A., Ramanathan R.K., Hayes M.J., Egorin M.J. Liquid chromatographic-mass spectrometric assay for quantitation of imatinib and its main metabolite (CGP 74588) in plasma. J Chromatogr B 2003, 791:39-44.
13. Widmer N., Béguin A., Rochat B., et al. Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction - liquid chromatography - ultraviolet absorbance detection. J Chromatogr B 2004, 803:285-292.
14. Roth O., Spreux-Varoquaux O., Bouchet S., et al. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: comparison with LC-MS/MS. Clin Chim Acta 2010, 411:140-146.
15. Haouala A., Zanolari B., Rochat B., et al. Therapeutic Drug Monitoring of new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry. J Chromatogr B 2009, 877:1982-1996.
16. Kutsev S, Kravchenko E, Turkina A. Imatinib blood level test in Russian federation. EUTOS Blood Level Testing Summit, November 16-17, 2009, Bordeaux, France (lecture).
17. Velpandian T., Mathru R., Agarwal N.K., Arora B., Kumar L., Gupta S.K. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B 2004, 804:431-434.
18. FDA Guidance for Industry. Bioanalytical Method Validation. 2001.
19. Shah V.P., Midha K.K., Findlay J.W.A., Hill H.M., et al. Bioanalytical method validation - a revisit with a decade of progress. Pharmaceut Res 2000, 17:1551-1557.
20. Matuszewski B.K., Constanzer M.L., Chavez-Eng C.M. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003, 75:3019-3030.
21. Bakhtiar R., Khemani L., Hayes M., Bedman T., Tse F. Quantification of the anti-leukemia drug STI571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal 2002, 28:1183-1194.
22. le Coutre P., Kreuzer K.A., Pursche S., et al. Pharmacokinetics and cellular uptake of imatinib and its main metabolite CGP74588. Cancer Chemother Pharmacol 2004, 53:313-323.
23. 1-acid glycoprotein. Br J Clin Pharmacol 2006, 62:97-112.